Durability Of Complete Response After Blinatumomab Therapy For Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Andreas Viardot,Georg Hess,Ralf C. Bargou,Nicholas J. Morley,Giuseppe Gritti,Maria-Elisabeth Goebeler,Karim Iskander,David Cohan,Alicia Zhang,Janet Franklin,Luke Coyle

LEUKEMIA & LYMPHOMA（2020）

引用 17|浏览0

暂无评分

摘要

Despite advances in standards of care, the prognosis of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains poor. In these patients, 50–74% fail to respond to next line therapy,...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要